Clinical Trial Update: Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating urelumab in combination with rituximab for relapsed/refractory or high-risk untreated chronic lymphocytic leukemia has been withdrawn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Rituximab (rituximab)
• Urelumab (urelumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: WITHDRAWN